Cordis Preparing For 2002 Cypher Stent Approval, Initial Supply Constraints
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis says it will be able to meet demand in less than half of the U.S. coronary stent market if FDA approval of the sirolimus-eluting Cypher comes before the end of the year